ALVO - Alvotech Polifarma ink pact to sell potential Eylea biosimilar in Turkey

2023-05-10 06:21:20 ET

• Alvotech ( NASDAQ: ALVO ) signed an exclusive agreement with Polifarma Ilac San. ve tic. for the commercialization in Turkey of AVT06, a proposed biosimilar to Regeneron Pharmaceuticals ( REGN ) and Bayer's ( OTCPK:BAYRY ) ( OTCPK:BAYZF ) Eylea (aflibercept).
• Under the agreement, Polifarma will handle market registration and commercialization of AVT06 in Turkey, while Alvotech will be responsible for developing and manufacturing the therapy.
• Alvotech noted that AVT06 is currently in clinical development. In July 2022, Alvotech said it started a patient study to evaluate AVT06 and Eylea in adult patients with neovascular (wet) age-related macular degeneration (AMD).

For further details see: